Understanding Recent Advances in Non-amyloid/non-tau (NANT) Biomarkers and Therapeutic Targets in Alzheimer's Disease

Overview

Journal Alzheimers Dement (N Y)

Date 2025 Jan 3

PMID 39748839

Authors

Linda J Van Eldik

Eric R Siemers

Emily C Collins

Michael Gold

David Henley

Peter Johannsen

Hans J Mobius

Melanie Shulman

Jin Zhou

Maria Carrillo

Christopher Weber

Affiliations

Soon will be listed here.

Abstract

Highlights: The Alzheimer's Association Research Roundtable (AARR) convened leaders from industry, academia, and government to review the current state of non-beta amyloid and non-tau (NANT) targets on underlying Alzheimer's disease (AD) pathophysiology.The totality of scientific and clinical evidence supports the hypothesis that emerging NANT targets play a role in cognitive decline and neurodegeneration in AD. New biomarkers based on NANT targets must be globally developed and implemented with specific consideration of fluid biomarkers as a cost-effective clinical option, to ensure better, more equitable treatment options for AD.

References

Hansson O . Biomarkers for neurodegenerative diseases. Nat Med. 2021; 27(6):954-963. DOI: 10.1038/s41591-021-01382-x. View

Orefice L, Shih C, Xu H, Waterhouse E, Xu B . Control of spine maturation and pruning through proBDNF synthesized and released in dendrites. Mol Cell Neurosci. 2015; 71:66-79. PMC: 4761458. DOI: 10.1016/j.mcn.2015.12.010. View

Quiroz Y, Aguillon D, Aguirre-Acevedo D, Vasquez D, Zuluaga Y, Baena A . Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease. N Engl J Med. 2024; 390(23):2156-2164. DOI: 10.1056/NEJMoa2308583. View

Selkoe D . Alzheimer's disease is a synaptic failure. Science. 2002; 298(5594):789-91. DOI: 10.1126/science.1074069. View

Ewers M, Franzmeier N, Suarez-Calvet M, Morenas-Rodriguez E, Caballero M, Kleinberger G . Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med. 2019; 11(507). PMC: 7050285. DOI: 10.1126/scitranslmed.aav6221. View

Park J, Kam T, Lee S, Park H, Oh Y, Kwon S . Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. Acta Neuropathol Commun. 2021; 9(1):78. PMC: 8074239. DOI: 10.1186/s40478-021-01180-z. View

Nelson M, Liu P, Agrawal A, Yip O, Blumenfeld J, Traglia M . The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023; 26(12):2104-2121. PMC: 10689245. DOI: 10.1038/s41593-023-01480-8. View

Tijms B, Gobom J, Reus L, Jansen I, Hong S, Dobricic V . Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain. 2021; 143(12):3776-3792. PMC: 7805814. DOI: 10.1093/brain/awaa325. View

Feigin A, Evans E, Fisher T, Leonard J, Smith E, Reader A . Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022; 28(10):2183-2193. PMC: 9361919. DOI: 10.1038/s41591-022-01919-8. View

10.

Pagan F, Hebron M, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel E . Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2019; 77(3):309-317. PMC: 6990742. DOI: 10.1001/jamaneurol.2019.4200. View

11.

Litvinchuk A, Huynh T, Shi Y, Jackson R, Finn M, Manis M . Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. Ann Neurol. 2021; 89(5):952-966. PMC: 8260038. DOI: 10.1002/ana.26043. View

12.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Feldman H, Frisoni G . A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016; 87(5):539-47. PMC: 4970664. DOI: 10.1212/WNL.0000000000002923. View

13.

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

14.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

15.

Yang T, Tran K, Zeng A, Massa S, Longo F . Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies. Sci Rep. 2020; 10(1):20322. PMC: 7683564. DOI: 10.1038/s41598-020-77210-y. View

16.

Boros B, Greathouse K, Gentry E, Curtis K, Birchall E, Gearing M . Dendritic spines provide cognitive resilience against Alzheimer's disease. Ann Neurol. 2017; 82(4):602-614. PMC: 5744899. DOI: 10.1002/ana.25049. View

17.

Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton N, Blennow K . Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomark Insights. 2020; 15:1177271920950319. PMC: 7444114. DOI: 10.1177/1177271920950319. View

18.

Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H . CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018; 91(9):e867-e877. PMC: 6133624. DOI: 10.1212/WNL.0000000000006082. View

19.

Mattsson N, Cullen N, Andreasson U, Zetterberg H, Blennow K . Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019; 76(7):791-799. PMC: 6583067. DOI: 10.1001/jamaneurol.2019.0765. View

20.

Mintun M, Lo A, Evans C, Wessels A, Ardayfio P, Andersen S . Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021; 384(18):1691-1704. DOI: 10.1056/NEJMoa2100708. View